Effects of 0.1% Nepafenac on Vitreous Inflammatory Biomarkers in Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy

PHASE4CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

April 28, 2021

Primary Completion Date

December 1, 2021

Study Completion Date

December 1, 2021

Conditions
Proliferative VitreoretinopathyRhegmatogenous Retinal Detachment
Interventions
DRUG

Nepafenac 0.1% eyedrops

The study eye drops were nepavenac 0.1% eye drops (NEVANAC 0.1%®, Alcon Laboratories, Inc., Fort Worth, Texas). Subjects were instructed to use eye drops on the side of the eye with the ARR, three times daily for five days before and on the day of surgery. Written instructions and a daily checklist to record the eye drop schedule were provided to each subject.

DRUG

Control (placebo) group

Cenfresh® eye drops (Cendo pharmaceutical, Indonesia) for the control group. Subjects were instructed to use eye drops on the side of the eye with the ARR, three times daily for five days before and on the day of surgery. Written instructions and a daily checklist to record the eye drop schedule were provided to each subject.

Trial Locations (1)

Unknown

Department of Ophthalmology, Faculty of Medicine Universitas Indonesia Cipto Mangunkusumo Hospital, Jakarta

All Listed Sponsors
lead

Indonesia University

OTHER